Microbiome and cancers, with focus on genitourinary tumors
- 1Section of Pathological Anatomy, Polytechnical University of Marche, Italy
- 2Oncology Unit, Ospedale Generale Provinciale Macerata, Italy
- 3Division of Oncology, Policlinico S.Orsola Malpighi, Italy
- 4Department of Pathology and Laboratory Medicine, Indiana University, United States
- 5Department of Pathology and Surgery, Universidad de Córdoba, Spain
In the few years, a close biological relationship has emerged among the microbiome of the gut, the metabolism of the body, as well as the immune system including cancer development. With the advent of high-throughput next generation sequencing techniques, the exploration and the understanding of the mechanisms of the complex microbial network that colonize our body areas have started. Results shows that microbiome might be a novel prognostic, diagnostic, prophylactic, and therapeutic tool. In particular, in RCC patients gut microbiome composition could influence primary resistance to PD-1blockade. Antibiotic therapy (ATB) inhibits the clinical benefit of immunotherapy of patients with cancer in an advanced stage and represent a predictor of resistance to PD-1 blockade. Pioneer studies on bladder and prostate cancer (PCa) patients’ microbiome have shown significant differential abundance in bacterial composition compared to healthy controls. Moreover, the identification of microbiome-derived metabolites and related pathways significantly different in PCa samples compared to controls has been used to develop a microbiome profile that predicts PCa risk. Even at its onset, the research on microbiome might represent a step forward in understanding the mechanisms underlying oncogenesis, progression and resistance to therapy of cancers.
Every individual is characterized by a specific ‘enterotype’, based on the major components of her/his microbiome (i.e., collection of host and microorganism genomes and environmental conditions in an ecosystem) of the gut influenced by diet and geography. This is also influenced by the effects of the organisms present in the infancy as well as the type and pattern of the individual immune system (1).
In the few years, a close biological relationship has emerged among the microbiome of the gut, the metabolism of the body, as well as the immune system including cancer development. With the increasing availability of high-throughput sequencing, single-cell transcriptomics and mass spectrometry for a very precise characterization of single enteric, neoplastic and immune cells, and more extensive databases of organisms already sequenced, experimental exploration of this network has become possible. These advances have also included “culturomics” in order to make an ever-expanding portion of the microbiota investigable, and sophisticated bioinformatics implements in order to achieve data deconvolution and combination. In 2008 the Human Microbiome Project (HMP) started to characterize the microbial communities from 300 healthy individuals, providing one of the broadest microbial genome database targeting different body sites: nares, oral cavity, skin, gastrointestinal tract, breast and urogenital tract (2). (Figure 1)
2. Microbiome and cancer
In 2017 many experimental studies has been published to demonstrate the importance of single bacterial species on the intestine, the individual immune response and cancer progression and response to therapy. One of the first unexpected evidence was that secondary tumor deposits in patients with colorectal cancers include bacteria, such as Fusobacterium species, including Bacteroides, Prevotella and Selenomonas species, its associated microbiome. These findings demonstrated the microbiome stability between paired primary and metastatic tumors. Antibiotic treatment of Fusobacterium-positive colon cancers mice-xenografts reduces tumor growth, cancer cell proliferation along with Fusobacterium load, which favors the hypothesis that Fusobacterium species is associated with neoplastic progression (3-4).
In breast cancer, bacterium Methylobacterium radiotolerans was found relatively enriched compared to normal adjacent tissue from the same patient. Furthermore, bacterial DNA load was reduced in cancer samples vs. healthy tissue and correlated inversely with advanced disease (5-6). In the distal esophagus the impact of the microbiome in the pathogenesis of reflux-related disorders and in the development of intestinal metaplasia is well demonstrated. Patients with esophagitis and Barrett's esophagus have a greater proportion of gram-negative anaerobes/microaerophiles respect the normal controls. This altered microbiome may promote Barrett's metaplasia and progression to adenocarcinoma (7-8). The compositions of bacteria community and the throat biodiversity in laryngeal carcinoma patients compared to a control population were different and might be a risk factor for laryngeal carcinoma (9).
The most clinical-affecting evidence regarding cancer microbiome is its contribution to therapy resistance. In pancreatic cancer the most common species identified belong to the Enterobacteriaceae and Pseudomonadaceae families. Enterobacteriaceae express a bacterial enzyme cytidine deaminase (CDD) isoform that confer resistance to gemcitabine. Supporting this, co-treatment with the antibiotic ciprofloxacin abrogate the gemcitabine resistance in colon cancer mouse models (10).
On the other side, there are evidence that corroborate the hypothesis of a protection role of microbiome toward neoplastic changes. Hence, results shows that individuals with microbiota linked to a plant diet are the ones with a lower incidence of cancer of the colon (11). Such a diet stimulates bacteria to produce short-chain fatty acids (SCFAs), in particular butyrate, propionate and acetate. These fatty acids show an anti-inflammatory property through the induction of T-regulatory cells of colonic tissues. Connections of microbiome, production of short-chain fatty acids and immune system become more interesting when researchers started to explore the influence of microbiome in relation to immunotherapy drugs response.
3. Microbiome and immunotherapy drugs response
Immunotherapy based on and programmed death-ligand 1 (PD-L1)- and programmed death 1 (PD-1)-targeted antibodies has profoundly modified the prognostic and therapeutic landscape for many types of tumors, with demonstrated efficacy against renal cell carcinoma (RCC), non–small cell lung cancer (NSCLC), and melanoma. PD-L1 tissue expression is a poor prognostic factor as well as predictor of good responses from both PD-1 and PD-L1 inhibitors in urothelial carcinoma (UC) and RCC (12). In a recent meta-analysis on the expression of PD-1 and PD-L1 in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors, odds ratios of objective response in PD-L1 –positive patients compared with PD-L1–negative patients was 2.34 for RCC and 2.20 for bladder cancer(13). Liu et al. also confirmed that “patients with higher ratios of PD-L1-positive cells responded significantly better to both PD-1 and PD-L1 antibodies than those with lower ratios of PD-L1-positive cells” (14).
Each PD-1/PD-L1 drug approved by FDA is associated with a PD-L1 a immunohistochemistry (IHC)-based tissue assay. IHC-based PD-L1 assay is basically utilized to potentially predict the response to anti-PD-1 or/and anti-PD-L1 therapies. A fraction of patients with a negative IHC assay can show a response. This means that identification and utilization of other biomarkers is of great importance for a better selection of patients who might respond to such therapies.
Primary resistance to Immune checkpoint inhibitors (ICIs) has been linked to different factors, including poor intrinsic antigenicity of malignant cells, lack of priming by potentially immunogenic pretreatment with radio- or/and chemotherapy (15), poor antigen presentation at the time of the priming phase (16), immunosuppression exerted locally by extracellular metabolites (17), and functional exhaustion of lymphocytes infiltrating the tumor (18-19). On the contrary, high mutational burden and high immunogenic antigenicity of malignant cells are in favor of better response to ICIs (20,21). Recently Routy et al. demonstrated that abnormal gut microbiome composition could have an influence on primary resistance to PD-1blockade in mice xenografts and patients with cancer. In particular they showed that the clinical benefit of ICIs in patients with cancer in an advanced stage is inhibited by antibiotic therapy (ATB) (22). They tested the effect of ATB on patients with advanced UC, RCC or NSCLC, who had received PD-1/PD-L1mAb following one or several previous therapies. Progression-free survival (PFS) and overall survival (OS) were shorter significantly in the ATB-treated cohort when either all patients were combined together or when individual cancer types were investigated. In univariate and multivariate analyses, ATB was a predictor factor for resistance to PD-1 blockade, not dependent from traditional prognostic markers in RCC and NSCLC. In order to evaluate the composition of the microbiota of the gut, they used quantitative metagenomics with analysis of the data in a reference catalog of 9.9 million genes. The greatest richness of the samples analyzed at the levels of metagenomic species (MGS) and gene count was correlated with the clinical response. This was defined by the lack of progression of disease 6 months following the initiation of ICIs.
Akkermansia muciniphila (A. muciniphila) was the commensal associated most significantly with excellent clinical outcomes in both RCC and NSCLC. When analyzing memory T cell responses from the peripheral blood of the patients, stimulated against microbiota following initiation of PD-1 blockade, the only immune response linked with the clinical benefit at the time of immunotherapy was the Th1 and Tc1 cell reactivity against A. muciniphila. This immunomodulatory effect might be explained by the production of SCFAs, such as propionate and acetate, by A. muciniphila. These short-chain fatty acids are ligands of the two orphan G-protein–coupled receptors 41 and 43 (GPR41 and GPR43). The former regulates the tumor cells apoptosis induced by SCFA and so exert a tumor suppressor activity. Furthermore, propionate produced by the bacterium inhibits histone deacetylases and thus increase the histone hyperacetylation.
The inhibition of the expression of Histone Deacetylases (HDACs) has several effects, ranging from a pro-apoptotic activity to a pro-inflammatory response. By opening cell chromatin and thus increasing the DNA accessibility to transcription factors, the histone hyperacetylation induces overexpression of caspases 6, 7, and 8, including caspase 3, and reduces the inhibitor of apoptosis (IAP) family expression (23). The inhibition of expression the HDACs activates the mTOR-S6K and STAT3 pathways. All this stimulates Th17, Th1, FoxP3+, and IL-10+ T cells as well as the production of IL-10, IFN-g, and IL-17 in CD8+ T cells in both Tc1- and Tc17-cell subsets (24). Moreover, propionate promotes T-cell migration by increasing the expression of intercellular adhesion molecule 1 (ICAM-1) and E-selectin on endothelial cells (25-26). (Figure 2)
Derosa et al. demonstrated the effect of ATB in patients with RCC and NSCLC treated with anti-PDL1 mAb monotherapy or combination therapy. In patients with RCC, ATB compared with no ATB was linked with an increased risk of progressive disease, shorter PFS, and shorter OS. Similar rates were also obtained in the NSCLC cohort (27). Researchers are now planning to transfer fecal bacteria from patients who respond to treatment with checkpoint inhibitors into the intestine of non-responder patients. This process is currently called “fecal microbiome transplant”. Microbiota composition might be manipulated also by the application of foods and prebiotics. The prevalence of a subspecies selected by diet rather than others could modify the population predisposition to a specific disease and also the response to therapy of cancer patients (28). Fecal microbiota transplant, although not being probiotic, could be considered a fermented food, given the microbes and nutrients present.
4. Microbiome in bladder and prostate cancer
Of great interest is the urinary microbiota profile investigated by Wu et al. They analyzed DNA from urine pellet collected from male patients with urothelial carcinoma and non-neoplastic controls. They observed enrichment of some bacterial genera (such as Sphingobacterium, Anaerococcus and Acinetobacter) and decrease of others (such as Roseomonas, Proteus and Serratia) in the group with cancer in comparison with the control group. Patients with high risk of recurrence and progression had an enrichment of Herbaspirillum, Porphyrobacter, and Bacteroides. This means these bacteria can be considered as potential biomarkers in risk stratification (29).
In the last year, interesting results have emerged by investigations on the microbiome in PCa patients. The microflora of tumor, peri-tumor, and benign prostate tissue samples have recently been characterized by massive ultradeep pyrosequencing. Interestingly, differences in microbial populations among paired tumor/peri-tumor and non-tumor prostate tissues have been detected. This finding generates the hypothesis that the distribution of bacterial microbes varies according to the nature of tissue within the same gland. This suggests a pathophysiological association between the local microbial niche and composition, and the tumor itself (30-32). (Table 1)
A case-control pilot study has been conducted by Golombos et al. to demonstrate the impact of the gut microbiota on PCa pathogenesis. They performed a computational genomics analysis on stool samples of men with benign prostatic conditions and men with intermediate or high risk clinically localized PCa. Biologically significant abundance differences of bacteria species and 23 metabolic differentially abundant pathways were identified between the two cohorts (33). Likewise, analyses on the urinary microbiome showed a prevalence of uropathogens and pro-inflammatory bacteria differentially abundant in PCa patients compared to healthy subjects in urine collected from men prior to biopsy for PCa (34).
Liss and colleagues developed a microbiome-derived risk profile for PCa, derived from altered metabolic pathways, comparing the taxonomic composition of samples (64 with PCa and 41 without ) of rectal swab collected two weeks before prostate biopsy (35). Even though the differences between the two groups are not impressive, these results are hypothesis-generating and pave the way to further evaluate the manipulation of aberrant microbiomes in order to reduce PCa risk (36).
The composition of the microbiota in the gut is influenced by oral androgen receptor axis-targeted therapies (ATT) in prostate cancer patients. Results on fecal microbiota profile shows abundance of species linked to response to anti-PD-1 immunotherapy, including Ruminococcaceae spp and A. muciniphila, and an greater representation of bacterial gene pathways that are involved in steroid biosynthesis as well as steroid hormone biosynthesis in the fecal microbiota of men under ATT (37-38). Additional studies are needed to evaluate whether the gut microbiota can influence clinical responses to ATT, and modulate the anticancer effects of future therapies, including immunotherapy.
As regards to genitourinary tumors, there are only few trials ongoing . One to take into consideration is a prospective study on prostate cancer and breast cancer patients who undergoing to two different standard of care radiation regimens. Exposure to radiation can impact immune cells that are present in the blood and also the underlying microbiota. The aim of this study is to study microbial changes and how these changes correlate with alteration in immune mediators (i.e., lymphocytes, cytokines) present in blood samples before, during and after radiation by collecting stool specimens at baseline, end of radiation therapy and during the follow up (ClinicalTrials.gov Identifier: NCT03383107).
The host and the microbiota share a complex balanced relationship that can be overthrown in a state of dysbiosis consequent to environmental changes. Alteration of this balance could lead to promotion of inflammatory diseases and cancer. There is evidence showing that the activity of microbiota in the restoration of response to immune checkpoint inhibitors involves both the immune and cancer cells. Stimulating recall Th1 responses against A. muciniphila improves immunosurveillance in cancer patients. Microbiome composition might be a novel biomarker of response to ICIs and also a therapeutic opportunity for unresponsive patients. In patients with RCC, antibiotic therapy was linked with an increased risk of progressive disease, shorter PFS, and shorter OS. Pioneer studies on bladder and prostate cancer patients’ microbiome pave the way to the investigation of a possible novel prognostic, diagnostic, and therapeutic tool.
Keywords: microbiome, Resistance to therapy, Renal cell carcinoma, Immunotherapy, PD-1 blockade, Antibiotic therapy, prostate cancer
Received: 13 Aug 2018;
Accepted: 04 Mar 2019.
Edited by:Ja Hyeon Ku, Department of Urology, College of Medicine, Seoul National University, South Korea
Reviewed by:Sergio Bracarda, Azienda Ospedaliera S.Maria, Italy
Copyright: © 2019 Cimadamore, Santoni, Massari, Gasparrini, Cheng, Lopez-Beltran, Montironi and Scarpelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Rodolfo Montironi, Polytechnical University of Marche, Section of Pathological Anatomy, Ancona, Italy, firstname.lastname@example.org